Literature DB >> 8620675

Lack of pharmacokinetic interaction between zileuton and phenytoin in humans.

E Samara1, J H Cavanaugh, D Mukherjee, G R Granneman.   

Abstract

A randomised double-blind crossover study was undertaken in 20 healthy adult male volunteers to assess the effects of multiple oral dose administration of zileuton (600mg every 6 hours for 8 days) on the single dose pharmacokinetics of phenytoin 300mg. Serial blood samples were collected up to 72 hours after phenytoin administration and plasma concentrations were determined by high performance liquid chromatography. Pharmacokinetic data were analysed utilising noncompartmental and Michaelis-Menten-based population pharmacokinetic analysis. Zileuton did not significantly alter the peak plasma concentration, time to peak plasma concentration, and area under the plasma concentration-time curve of phenytoin. Moreover, population analysis revealed no significant effect of zileuton on the Michaelis-Menten parameters of phenytoin. Thus, coadministration of multiple doses of zileuton (2.4 g/day) did not significantly affect the single dose pharmacokinetics of phenytoin.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8620675     DOI: 10.2165/00003088-199500292-00012

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  19 in total

Review 1.  5-lipoxygenase inhibitors and their anti-inflammatory activities.

Authors:  D G Batt
Journal:  Prog Med Chem       Date:  1992

2.  Effect of Zileuton (A-64077) on the 5-lipoxygenase activity of human whole blood ex vivo.

Authors:  P Sirois; P Borgeat; M Lauzière; L Dubé; P Rubin; J Kesterson
Journal:  Agents Actions       Date:  1991-09

3.  Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans.

Authors:  W M Awni; Z Hussein; G R Granneman; K J Patterson; L M Dubé; J H Cavanaugh
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

4.  The pharmacokinetic and pharmacodynamic interactions between the 5-lipoxygenase inhibitor zileuton and the cyclo-oxygenase inhibitor naproxen in human volunteers.

Authors:  W M Awni; R A Braeckman; J H Cavanaugh; C S Locke; P J Linnen; G R Granneman; L M Dubé
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

5.  The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air.

Authors:  E Israel; R Dermarkarian; M Rosenberg; R Sperling; G Taylor; P Rubin; J M Drazen
Journal:  N Engl J Med       Date:  1990-12-20       Impact factor: 91.245

6.  Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor.

Authors:  H R Knapp
Journal:  N Engl J Med       Date:  1990-12-20       Impact factor: 91.245

7.  5-lipoxygenase inhibitory activity of zileuton.

Authors:  G W Carter; P R Young; D H Albert; J Bouska; R Dyer; R L Bell; J B Summers; D W Brooks
Journal:  J Pharmacol Exp Ther       Date:  1991-03       Impact factor: 4.030

8.  Effect of BI-L-239, A-64077 and MK-886 on leukotriene B4 synthesis by chopped guinea pig lung and on antigen-induced tracheal contraction in vitro.

Authors:  T C Noonan; T Jamieson-Leclercq; S N Desai
Journal:  Prostaglandins       Date:  1992-12

9.  The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma.

Authors:  E Israel; P Rubin; J P Kemp; J Grossman; W Pierson; S C Siegel; D Tinkelman; J J Murray; W Busse; A T Segal; J Fish; H B Kaiser; D Ledford; S Wenzel; R Rosenthal; J Cohn; C Lanni; H Pearlman; P Karahalios; J M Drazen
Journal:  Ann Intern Med       Date:  1993-12-01       Impact factor: 25.391

10.  Phase II study of the safety and efficacy of a 5-lipoxygenase inhibitor in patients with ulcerative colitis.

Authors:  C Collawn; P Rubin; N Perez; J Bobadilla; G Cabrera; E Reyes; J Borovoy; D Kershenobich
Journal:  Am J Gastroenterol       Date:  1992-03       Impact factor: 10.864

View more
  2 in total

Review 1.  Zileuton, a leukotriene synthesis inhibitor in the management of chronic asthma. Clinical pharmacokinetics and safety.

Authors:  L M Dubé; L J Swanson; W Awni
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 2.  Role of population pharmacokinetics in drug development. A pharmaceutical industry perspective.

Authors:  E Samara; R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-04       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.